View Older Stories View More Recent Stories
-
Moderna Announces Update on Investigational Pandemic Influenza Program
-
Moderna to Present at Upcoming Conferences in June 2025
-
Biotech stocks Q1 earnings review
-
Moderna (MRNA) files FDA application for Spikevax formula
-
Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine
-
Kennedy Jr.'s 'MAHA' Report Expected to Criticize Chemicals in Food, Lobbyists and Vaccines, Sources Say -- WSJ
-
Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA), PT $198
-
Moderna (MRNA) has voluntarily withdrawn the pending BLA for mRNA-1083
-
Moderna Provides Update on BLA Submission for Combination Vaccine Against Influenza and COVID-19
-
FDA Mandates Trials For Covid Boosters For Healthy Kids, Adults - NEJM
-
HHS plans to stop recommending Covid shots for children and pregnant women - WSJ
-
RFK Jr.'s HHS to Stop Recommending Routine Covid Shots for Kids, Pregnant Women -- WSJ
-
Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025
-
Trump: Dr. Casey Means Nominated For Surgeon General
-
Moderna (MRNA) call put ratio 1 call to 1.2 puts amid wide price movement
-
Moderna (MRNA) sees mid-day weakness
-
Berenberg Reiterates Hold Rating on Moderna (MRNA)
-
Moderna (MRNA) Tops Q1 EPS by 66c; offers guidance
-
Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates
-
Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
-
Pharma stocks slide after Trump signals tariffs on sector
-
Moderna (MRNA) to Showcase Extensive Infectious Disease Research
-
Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025
-
Bernstein Assesses U.S. Biopharma Stocks Amid Tariff Risks
-
Brookline on Moderna (MRNA): 'Australia Authorizes RSV Vaccine,mRNA-1345 for Adults 60 Years and Older; Supports Our Outlook'
-
Truist: 'Expect Some Pressure On Dr. Marks' Resignation'
-
Moderna (MRNA) Falls 12% on Concerns About Vaccine Regulations
-
Moderna (MRNA) Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults
-
Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults
-
Moderna (MRNA) PT Lowered to $39 at Bernstein Amid 'Policy Uncertainty'
-
CDC Plans Large Study Into Potential Connections Between Vaccines and Autism - Reuters
-
Moderna (MRNA) call put ratio 1.3 calls to 1 put amid wide price movement
-
Genevant Sciences (ROIV) and Arbutus Biopharma (ABUS) Initiate International Patent Infringement Enforcement Actions Against Moderna
-
Moderna (MRNA) Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine
-
Moderna's Bird Flu Shot Contract Under Review By Trump Admin - Bloomberg
-
Moderna to Present at Upcoming Conferences in March 2025
-
Clorox (CLX) gains 2.7% on new virus concerns
-
Moderna (MRNA) Strength tied to Speculation About New Coronavirus
-
RBC Capital on Moderna (MRNA): 'Next Few Months Key'
-
Barclays Downgrades Moderna (MRNA) to Equalweight
-
Bernstein SocGen Group Reiterates Market Perform Rating on Moderna (MRNA)
-
Moderna (MRNA) PT Lowered to $25 at Wolfe Research
-
Moderna (MRNA) Misses Q4 EPS by 18c; offers guidance
-
Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates
-
Moderna faces revenue pressures as analysts cut estimates ahead of earnings
-
RFK, Jr. said confirmed
-
Moderna (MRNA) call put ratio 1.6 calls to 1 put into quarter results
-
Moderna (MRNA) call put ratio 1.4 calls to 1 put into quarter results
-
Moderna (MRNA) on Watch as RFK Jr. Clears Senate Committee, Will Get Full Vote To Head HHS
-
Moderna to Report Fourth Quarter and Full Year 2024 Financial Results on Friday, February 14, 2025

